Skip to main content
SpringerLink
Log in

Infliximab treatment in refractory Kawasaki syndrome

  • Clinical Brief
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Kawasaki syndrome is one of the commonest vasculitides in pediatric age group with devastating consequences if not treated early. Intravenous Gammaglobulin leads to rapid amelioration of clinical symptoms and significantly decreases the risk of development of coronary artery aneurysms. Occasionally, Kawasaki disease may be resistant to I/V IgG. We present our experience with one such patient who ultimately respondend to infliximab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease acute rheumatic fever. J Pediatr 1991; 119: 279–282.

    Article  CAS  PubMed  Google Scholar 

  2. Yanagawa H Yashiro M, Nakamura Y, Kawasaki T, Kato H. Results of 12 nationwide epidemiological incidente surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med 1995; 149: 779–783.

    CAS  PubMed  Google Scholar 

  3. Jane WN, Masto T, Michael AG. Pediatrics 2004; 114: 1708–1733.

    Article  Google Scholar 

  4. Jane CB, Wildert HM, Sarmishta BH. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662–667.

    Article  Google Scholar 

  5. Sridhar MR, Himanshu G, Deepa A, Rakesh L, Kabra SK. Kawasaki Disease: Are we missing the Diagnosis? Indian J Pediatr 2005; 72: 873–875.

    Article  CAS  PubMed  Google Scholar 

  6. Jane CB, Chisato S. Gentic Variations in the Receptor-Lignad Pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki Disease. J Infect Disease 2005; 192: 344–349.

    Article  Google Scholar 

  7. Donald YML, Ramzi SC. Endothelial Cell Activation and High Interleukin-1 Secretion in the pathogenesis of acute Kawasaki disease. The Lancet 1989; 2: 1298–1301.

    Google Scholar 

  8. Newburger JW, Sleeper LA, McCrindle BW, Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki Disease. N Engl J Med 2007; 356: 663–675; doi: 10.1056/NEJMoa061235.

    Article  CAS  PubMed  Google Scholar 

  9. Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol. 1997; 24: 1179–1185.

    CAS  PubMed  Google Scholar 

  10. Gupta MM, Rao PS. Current prespectivas in Kawasaki disease. Indian JPediatr 2005; 72: 621–629.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Hospital, Midas Heights, Nagpur, India

    Meenakshi Girish & Girish Subramaniam

Authors
  1. Meenakshi Girish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Girish Subramaniam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meenakshi Girish.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Girish, M., Subramaniam, G. Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr 75, 521–522 (2008). https://doi.org/10.1007/s12098-008-0084-8

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-008-0084-8

Key words

Search

Navigation